Two Sigma Securities’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.51M | Buy |
+11,991
| New | +$1.51M | 0.19% | 124 |
|
|
2024
Q2 | – | Sell |
-2,380
| Closed | -$328K | – | 1932 |
|
|
2024
Q1 | $328K | Buy |
2,380
+777
| +48% | +$107K | ﹤0.01% | 586 |
|
|
2023
Q4 | $211K | Buy |
+1,603
| New | +$211K | ﹤0.01% | 845 |
|
|
2023
Q3 | – | Sell |
-4,839
| Closed | -$456K | – | 1778 |
|
|
2023
Q2 | $456K | Buy |
4,839
+458
| +10% | +$43.2K | 0.01% | 374 |
|
|
2023
Q1 | $443K | Buy |
4,381
+2,244
| +105% | +$227K | 0.01% | 439 |
|
|
2022
Q4 | $255K | Buy |
+2,137
| New | +$255K | 0.01% | 647 |
|
|
2022
Q3 | – | Sell |
-2,773
| Closed | -$270K | – | 1712 |
|
|
2022
Q2 | $270K | Buy |
+2,773
| New | +$270K | 0.01% | 577 |
|
|
2020
Q4 | – | Sell |
-4,036
| Closed | -$388K | – | 957 |
|
|
2020
Q3 | $388K | Buy |
+4,036
| New | +$388K | 0.01% | 188 |
|
|
2017
Q3 | – | Sell |
-7,973
| Closed | -$367K | – | 1080 |
|
|
2017
Q2 | $367K | Buy |
+7,973
| New | +$367K | 0.07% | 281 |
|
|
2017
Q1 | – | Sell |
-5,185
| Closed | -$201K | – | 1041 |
|
|
2016
Q4 | $201K | Buy |
5,185
+1,004
| +24% | +$38.9K | 0.07% | 454 |
|
|
2016
Q3 | $212K | Buy |
+4,181
| New | +$212K | 0.07% | 424 |
|